PBM Industry Files Second State Lawsuit in One Week

The Pharmaceutical Care Management Association (PCMA), the trade group representing pharmacy benefit managers (PBMs), filed a federal lawsuit in June 2026 seeking to shield PBMs from enforcement of Illinois' Prescription Drug Affordability Act, according to Healthcare Dive. The Illinois suit is the second major legal challenge PCMA has launched against a state PBM reform law in a single week — a sign of how intensely the industry is fighting back against a national wave of state-level oversight efforts.

For seniors and families managing Medicare drug coverage, this legal battle is worth watching. PBMs sit at the center of how prescription drug benefits are priced and managed, and the outcome of cases like this one could shape the landscape of drug affordability reforms for years to come.

What PBMs Do — and Why States Are Targeting Them

Pharmacy benefit managers are the intermediaries between drug manufacturers, insurance plans, and pharmacies. In practice, they negotiate rebates with drug makers, build and manage the drug formularies (covered drug lists) for health plans, and process prescription claims at the pharmacy counter. For Medicare Part D beneficiaries, PBMs are largely invisible — but they play a significant role in determining which drugs appear on a plan's formulary, what tier a drug is placed on, and ultimately what a member pays at the pharmacy.

Critics of the PBM industry — including patient advocacy groups, independent pharmacies, and an increasing number of state legislatures — have argued that the rebate system PBMs operate under can create incentives that favor higher-list-price drugs over lower-cost alternatives, and that a lack of transparency makes it difficult to verify whether savings are being passed through to patients and payers. Illinois' Prescription Drug Affordability Act is one of several state laws passed in recent years designed to bring more accountability and cost controls to drug pricing intermediaries.

The PCMA's lawsuit does not challenge the state's goals outright; rather, it appears to argue that federal law — most likely provisions related to how employee benefit plans are regulated — preempts Illinois from applying the law to PBMs in the way the state intends. This preemption strategy, which the industry has employed in legal challenges in other states, is a well-established avenue for contesting state-level regulation of entities that administer federally governed health benefits.

What This Legal Fight Means for Medicare Beneficiaries

Here is an important distinction for seniors to understand: Medicare Part D drug plans are governed primarily by federal law, not state law. That means state PBM reforms — even if they survive legal challenge — may have limited direct impact on what Medicare beneficiaries pay for their prescriptions. The federal government sets the rules under which Part D plans and their PBMs operate, and CMS (the Centers for Medicare and Medicaid Services) has its own regulatory authority over how drug pricing works within Medicare.

That said, the broader policy battle playing out in statehouses and courtrooms does carry indirect relevance for Medicare enrollees. When state reforms succeed, they can build political and regulatory momentum for federal action. Congress has already passed significant changes to Medicare drug pricing in recent years — most notably, the Inflation Reduction Act provisions that allow Medicare to negotiate drug prices directly with manufacturers for a set of high-cost drugs. How aggressively regulators and legislators pursue PBM reform at the federal level may be influenced, in part, by how state-level efforts fare in court.

The PCMA filing two major lawsuits in a single week also signals that the PBM industry views the current regulatory environment as an existential challenge to its business model. That level of legal activity could slow implementation of state reforms even if the underlying laws are eventually upheld, because injunctions and court delays can freeze enforcement during the litigation period.

For seniors enrolled in Medicare Part D, the more immediate and actionable lever remains plan comparison. Part D formularies, premiums, deductibles, and out-of-pocket caps vary considerably from plan to plan and change every year. The annual Open Enrollment Period — October 15 through December 7 — is the window to review your current plan's drug list and costs against available alternatives in your area. CMS's Medicare Plan Finder tool allows side-by-side comparisons based on your specific medications.

Key Takeaway for Medicare Enrollees

State PBM laws like Illinois' Prescription Drug Affordability Act are unlikely to directly change what Medicare Part D members pay for prescriptions, since Part D is governed by federal rules. However, the national trend toward PBM oversight — and the industry's aggressive legal resistance to it — reflects an ongoing debate over drug pricing transparency that could eventually influence federal Medicare policy. In the meantime, comparing Part D plans annually during Open Enrollment remains the most effective way for beneficiaries to manage drug costs. A licensed Medicare insurance agent or your State Health Insurance Assistance Program (SHIP) counselor can help you review your options at no cost.

A Pattern Worth Watching

The PCMA's back-to-back lawsuits in June 2026 underscore a broader tension in U.S. drug policy: states are increasingly willing to use their legislative authority to address drug cost concerns, while the industries subject to those laws are testing the limits of federal preemption doctrine to blunt those efforts. Courts will ultimately decide whether Illinois and states like it have the legal authority to regulate PBMs operating within their borders as the legislature intended.

For seniors and their families, the practical advice is to stay informed without being alarmed. The legal process is slow, and drug pricing reforms at any level of government rarely produce overnight changes in what you pay at the pharmacy counter. What does change year to year are your plan's specific formulary coverage, cost-sharing tiers, and network pharmacies — which is exactly why reviewing your Medicare drug plan each fall before Open Enrollment ends is one of the highest-value health-care decisions you can make.

If you have questions about how PBMs affect your current Part D plan, or want help comparing plans for the coming year, speaking with a licensed Medicare advisor or contacting your local SHIP office is a good starting point.